Starpharma STD gel in US tests
02 May, 2002 by Tanya HollisThe US government is paying for tests of a Melbourne-developed microbicide gel on macaque monkeys.
Progen's cancer drug in trials
01 May, 2002 by Daniella GoldbergBrisbane based Progen Industries has moved into Phase II clinical trials for their small molecule cancer drug PI-88.
Peplin researches pancreas
29 April, 2002 by Iain ScottPeplin Biotech has broadened its research pipeline for anti-cancer drugs that target diseases of the pancreas.
AGRF participates in schizophrenia study
26 April, 2002 by Melissa TrudingerThe Australian Genome Research Facility (AGRF) has played a crucial role in a major international study on the genetic causes of schizophrenia.
Virax HIV trial to begin
24 April, 2002 by Tanya HollisBiopharmaceutical research and development group Virax Holdings has announced it has finished recruiting patients to its HIV treatment trial.
Award for cancer immunology science
22 April, 2002 by Tanya HollisResearch proving that the immune system roams the body hunting out malignancies has led to an international award for a Melbourne scientist.
Aston hired to help transform AustCancer
17 April, 2002 by Daniella GoldbergPerth-based Australian Cancer Technology has appointed Dr Roger Aston, former Peptech CEO, to Executive Chairman to oversee their joint ventures, with London-based drug discovery services company Biofocus, and other cancer therapy projects.
Fear, regulatory black hole block diabetes trials
09 April, 2002 by Daniella GoldbergStringent guidelines and incomplete regulatory guidelines at home are forcing Australian and New Zealand biotechs offshore to test their novel diabetes treatments. But they are discovering that not everyone wants them.
Leukaemia research gives Bresagen gets a decade of market exclusivity
09 April, 2002 by Tanya HollisBresagen (ASX: BGN) has been granted a 10-year head start on the development of its anti-leukaemia drug E21R.
Garvan spin-off to trial monoclonal targets
08 April, 2002 by Daniella GoldbergG2 Therapies, a recent spin-off company from the Garvan Institute of Medical Research, will be launching into clinical trials of monoclonal targets to treat inflammatory diseases and cancer after raising $3.3 million in a first-round venture capital funding.
Gene cream offers hope for psoriasis sufferers
27 March, 2002 by Tanya HollisA Melbourne research group has become one of the first in the world to create a gene cream that successfully penetrates psoriasis lesions.
Metabolic to develop osteoporosis treatment
26 March, 2002 by Tanya HollisMetabolic Pharmaceuticals has announced a trans-Tasman licensing deal and research collaboration to develop a new osteoporosis treatment.
Aussie heart test given the go-ahead
26 March, 2002 by Tanya HollisAn Australian-developed, non-invasive test to measure arterial stiffness and heart function has been given the official nod from the United States.
Nerve drug fails in Phase II
22 March, 2002 by Tanya HollisA drug intended to reduce peripheral nerve damage in cancer patient has failed in a clinical trial.
Queensland gets closer to Texas
20 March, 2002 by Pete YoungCloser ties between a Texas biomedical research powerhouse and Queensland biotech institutes have been foreshadowed by Queensland Premier Peter Beattie.
